May 27, 2026, 09:00 ET Phase 3 REIMAGINE 13 trial results across a range of type 2 diabetes patient groups offer further insight into CagriSema, a novel amylin RA and a GLP-1 RA in a fixed-dose combination 1 Mid-stage trial data for investigational zenagamtide explore the safety and efficacy of the injectable formulation of the novel GLP-1/amylin-based treatment 2 New Ozempic and Wegovy data provide further evidence of semaglutide's strong cardiometabolic profile PLAINSBORO, NJ and BAGSVRD, Denmark, May 27, 2026 /PRNewswire/ -- Novo Nordisk today announced that new data from its cardiometabolic portfolio and pipeline will be showcased at the upcoming 2026 Scientific Sessions of the American Diabetes Association (ADA), taking place in New Orleans, June 58, 2026
Vitamin B12 for injection is a prescription-only medicine for good safety reasons
limited post-marketing data
Are high doses of vitamin B12 harmful
Cost and access : Both medications are expensive, and sermorelin for metabolic purposes is rarely covered by insurance, creating significant financial burden without guaranteed benefit
From these results we hypothesize that Dihexa-mediated protection relies, at least in part, on the activation of multiple downstream targets of the HGF/c-Met system (Akt-TOR and Ras-ERK)
